AbbVie, AndroGel partner owe $448 million in antitrust case - U.S. judge

A U.S. judge on Friday found that pharmaceutical company AbbVie Inc (ABBV.N) used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.